Increased serum levels of KiSS1-derived peptides in non-small cell lung cancer patient liquid biopsies and biological relevance.
KiSS1
Non-small cell lung cancer (NSCLC)
apoptosis
cisplatin
serum
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
19
01
2022
accepted:
12
05
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
13
8
2022
Statut:
ppublish
Résumé
The secreted products of the metastasis suppressor gene KiSS1-derived peptide levels in liquid biopsies from 60 NSCLC patients were assayed by ELISA. Preclinical experiments were carried out using quantitative real time polymerase chain reaction (qRT-PCR), ELISA, annexin V-binding and caspase activation assays. We compared KiSS1 release in 3 different matrices (serum, plasma and urine) and the highest levels were detectable in serum (range, 0-4.5 ng/mL). We observed increased levels of seric KiSS1 in NSCLC patients as compared to healthy donors. KiSS1 serum concentrations, after surgical procedure and/or adjuvant therapy. We observed differences among disease stages in urine samples. In preclinical models, Our results showing a peculiar modulation of KiSS1 levels in liquid biopsies of NSCLC patients and a regulation of cisplatin-induced apoptosis by KiSS1-derived peptides support an involvement of KiSS1 in cell response to treatment and highlight its promising features as a potential biomarker in NSCLC.
Sections du résumé
Background
UNASSIGNED
The secreted products of the metastasis suppressor gene
Methods
UNASSIGNED
KiSS1-derived peptide levels in liquid biopsies from 60 NSCLC patients were assayed by ELISA. Preclinical experiments were carried out using quantitative real time polymerase chain reaction (qRT-PCR), ELISA, annexin V-binding and caspase activation assays.
Results
UNASSIGNED
We compared KiSS1 release in 3 different matrices (serum, plasma and urine) and the highest levels were detectable in serum (range, 0-4.5 ng/mL). We observed increased levels of seric KiSS1 in NSCLC patients as compared to healthy donors. KiSS1 serum concentrations, after surgical procedure and/or adjuvant therapy. We observed differences among disease stages in urine samples. In preclinical models,
Conclusions
UNASSIGNED
Our results showing a peculiar modulation of KiSS1 levels in liquid biopsies of NSCLC patients and a regulation of cisplatin-induced apoptosis by KiSS1-derived peptides support an involvement of KiSS1 in cell response to treatment and highlight its promising features as a potential biomarker in NSCLC.
Identifiants
pubmed: 35958339
doi: 10.21037/tlcr-22-52
pii: tlcr-11-07-1315
pmc: PMC9359955
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1315-1326Commentaires et corrections
Type : CommentIn
Informations de copyright
2022 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-52/coif). The authors have no conflicts of interest to declare.
Références
Front Immunol. 2022 Feb 09;13:823618
pubmed: 35222404
World J Surg. 2012 Sep;36(9):2218-24
pubmed: 22552499
J Biol Chem. 2001 Sep 14;276(37):34631-6
pubmed: 11457843
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Brain Res. 2003 Dec 12;993(1-2):18-29
pubmed: 14642827
J Thorac Oncol. 2016 May;11(5):693-699
pubmed: 26921675
Oncogene. 2011 Jul 14;30(28):3163-73
pubmed: 21383688
Curr Oncol Rep. 2018 Jul 20;20(9):70
pubmed: 30030656
Pneumologie. 2017 Mar;71(3):151-163
pubmed: 28196386
Biochem Pharmacol. 2017 Jul 15;136:40-50
pubmed: 28404378
Int J Surg. 2012;10(9):551-4
pubmed: 22959969
Biochem Pharmacol. 2015 Mar 15;94(2):79-90
pubmed: 25600908
J Natl Cancer Inst. 2007 Feb 21;99(4):309-21
pubmed: 17312308
Urol Int. 2017;98(2):177-183
pubmed: 28095383
Cancer Res. 1997 Jun 15;57(12):2384-7
pubmed: 9192814
Nat Rev Cancer. 2014 Aug;14(8):535-46
pubmed: 25056707
Drug Resist Updat. 2019 Jan;42:12-21
pubmed: 30776659
Annu Rev Physiol. 2008;70:213-38
pubmed: 17988212
Cell Rep. 2016 Dec 13;17(11):2994-3009
pubmed: 27974212
J Clin Endocrinol Metab. 2005 Dec;90(12):6609-15
pubmed: 16174713
PLoS One. 2014 Jan 13;9(1):e84958
pubmed: 24454770
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Exp Neurol. 1999 Mar;156(1):71-83
pubmed: 10192778
Anticancer Res. 2018 Oct;38(10):5791-5798
pubmed: 30275201
Clin Chem. 2012 Jun;58(6):1061-3
pubmed: 22419748
Endocrinol Metab (Seoul). 2015 Jun;30(2):124-41
pubmed: 26194072
Nat Rev Cancer. 2021 Jan;21(1):37-50
pubmed: 33128031
Int J Biol Markers. 2002 Apr-Jun;17(2):148-51
pubmed: 12113584
Front Endocrinol (Lausanne). 2018 Aug 03;9:437
pubmed: 30123188